BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24379032)

  • 1. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus.
    Tafuri KS; Godil MA; Lane AH; Wilson TA
    J Clin Res Pediatr Endocrinol; 2013; 5(4):236-9. PubMed ID: 24379032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pioglitazone therapy in lean type 1 diabetes mellitus.
    Bhat R; Bhansali A; Bhadada S; Sialy R
    Diabetes Res Clin Pract; 2007 Dec; 78(3):349-54. PubMed ID: 17543413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
    Charbonnel B; DeFronzo R; Davidson J; Schmitz O; Birkeland K; Pirags V; Scheen A;
    J Clin Endocrinol Metab; 2010 May; 95(5):2163-71. PubMed ID: 20237169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.
    Sourij H; Zweiker R; Wascher TC
    Diabetes Care; 2006 May; 29(5):1039-45. PubMed ID: 16644634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
    Wallace TM; Levy JC; Matthews DR
    Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.